<DOC>
	<DOCNO>NCT00667628</DOCNO>
	<brief_summary>The purpose study determine whether TAC-101 combine Transcatheter Arterial Chemoembolization ( TACE ) effective TACE alone slow tumor activity patient advance hepatocellular carcinoma . The study also look safety TAC-101 combination TACE .</brief_summary>
	<brief_title>Phase 2 Study TAC-101 Combined With Transcatheter Arterial Chemoembolization ( TACE ) Versus TACE Alone Japanese Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>Advanced metastatic hepatocellular carcinoma ( HCC ) treatable surgical approach locoregional therapy hepatic artery hemoembolization radiofrequency ablation ( RFA ) effective control localized tumor . Transcatheter arterial chemoembolization ( TACE ) commonly perform procedure treatment unresectable liver tumor select patient . The TACE procedure delivers highly concentrate drug tumor arrest blood flow . Most patient intrahepatic recurrence tumor follow TACE . Studies TAC-101 , synthetic retinoid , indicate although TAC-101 may induce tumor regression , appear stabilize effect , prolong survival expect historically . This study design randomize , double-blind , placebo-controlled , parallel-group , phase 2 study patient advance HCC undergone TACE procedure , conduct multiple sit Japan , determine administration TAC-101 enhance benefit TACE procedure .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>A patient must meet follow inclusion criterion eligible enrollment study undergo first TACE procedure study : 1 . Has HCC diagnosis histology follow noninvasive criterion observe either enrollment past . One imaging technique ( CT scan magnetic resonance image [ MRI ] unenhanced plus hepatic arterial phase portal venous phase ) show characteristic feature focal lesion &gt; 20 mm arterial vascularization Two dynamic image technique ( CT scan , MRI unenhanced plus hepatic arterial phase portal venous phase ) show characteristic feature coincidentally focal lesion 1020 mm arterial vascularization . 2 . Is TACE naïve receive recent TACE procedure least 120 day sign ICF . 3 . Eligible receive TACE schedule receive TACE . 4 . Must ≥ 20 year age . 5 . Is amenable treatment curative surgery , transplant , percutaneous ablation , include RFA , percutaneous ethanol injection therapy ( PEIT ) percutaneous microwave coagulation therapy ( PMCT ) . 6 . Must lesion liver confirm nodular type demonstrate substantial hypervascularity CT scan MRI unenhanced plus hepatic arterial phase portal venous phase perform prior first TACE study follow tumor feature : If ≥ 4 intrahepatic lesion , lesion &lt; 30 mm . , regardless number lesion , long diameter least one intrahepatic lesion ≥ 30 mm ) . No vascular invasion main trunk first order branch portal vein . No extrahepatic tumor spread . The absence extrahepatic abdominal tumor must confirm . 7 . Has adequate organ function define follow criterion : White blood cell ( WBC ) count &gt; 3,000/mm3 ; Platelet count &gt; 60,000/mm3 ; Hemoglobin &gt; 8.0 gram ( g ) /deciliter ( dL ) ; Aspartate transaminase ( AST ) &lt; 5 x upper limit normal ( ULN ) ; Alanine transaminase ( ALT ) &lt; 5 x ULN ; Total bilirubin &lt; 2.0 mg/dL ; Albumin ≥ 2.8 g/dL ; Serum creatinine ≤ 1.5 mg/dL ; International normalize ratio ( INR ) ≤ 2.0 ; Triglyceride ≤ 2.5 x ULN . 8 . Must ChildPugh classification ≤ 8 . 9 . Must Cancer Liver Italian Program ( CLIP ) 60 score 0 , 1 , 2 3 ( Appendix B ) . 10 . Must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 11 . Must willing able comply schedule visit , treatment plan , laboratory test , study procedure . 12 . Must provide write informed consent prior implementation study assessment procedure . Patients exclude participation study follow condition observe undergo first TACE procedure : 1 . Patient long diameter intrahepatic lesion ≥ 100 mm . 2 . Patient infiltration type HCC . 3 . Patient extrahepatic metastasis HCC include regional lymph node metastasis ( include lymph node organ ) . 4 . Patient systemic chemotherapy ( eg , sorafenib , doxorubicin ) , immunotherapy , biologic therapy radiotherapy HCC , treatment TAC101 . 5 . Patient receive treatment follow within specified time frame : Any major surgical procedure within 28 day prior sign ICF ; Any transfusion , treatment blood component preparation , albumin preparation , granulocyte colony stimulate factor ( GCSF ) within 14 day prior sign ICF ; Any local therapy alcohol injection , radiofrequency/ultrasound ablation , intraarterial chemotherapy ( transcatheter arterial injection ) HCC perform within 28 day prior sign ICF ; Any investigational agent within 28 day prior sign ICF . 6 . Patient ascites , pleural effusion pericardial fluid refractory diuretic therapy . 7 . Patient clinical symptom hepatic encephalopathy . 8 . Patient active uncontrolled clinically serious infection exclude chronic hepatitis . 9 . Patient history gastrointestinal ( GI ) bleed last 3 month . 10 . Patient previous concurrent malignancy except situ carcinoma cervix , solid tumor treat curatively without evidence recurrence least 3 year prior study . 11 . Patient uncontrolled metabolic disorder nonmalignant organ systemic disease secondary effect cancer induce high medical risk and/or make assessment survival uncertain . 12 . Patient history deep vein thrombosis ( DVT ) , pulmonary embolism ( PE ) , myocardial infarction ( MI ) , cerebrovascular accident ( CVA ) , transient ischemic attack ( TIA ) , unstable angina pectoris , significant thromboembolic event ( TE ) last 3 year . 13 . Patient clinically significant electrocardiogram ( ECG ) abnormality . 14 . Patient GI disease result inability take oral medication . 15 . Patient know allergy hypersensitivity TAC101 , doxorubicin , epirubicin , anthracyclines , anthracenediones component use study drug formulation . 16 . Patient known hypersensitivity iodinate contrast medium . 17 . Patient receive therapeutic regimen anticoagulant . However , use low dose anticoagulant prophylactic care indwell venous access device permit . 18 . Patient take medication know suspect predispose patient increase risk VTE ( eg , oral contraceptive , hormone replacement therapy , megestrol acetate ) . 19 . Patient take azoles tetracycline , potential drug interaction . 20 . Women intend become pregnant pregnant lactate men able procreate refuse use highly effective method birth control treatment study medication 6 month thereafter .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>